NYSE · LLY
Eli Lilly and Company
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
Loading market information…
NASDAQ · GPCR · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Structure Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 76.88% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Structure Therapeutics Inc.’s next earnings report is currently expected on Nov 5, 2026, with estimated earnings per share of -$0.33. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Structure Therapeutics Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Structure Therapeutics Inc., an international biopharmaceutical company currently in its clinical development phase, is committed to creating and providing groundbreaking oral therapies for various chronic diseases that lack adequate treatment options. The company's primary investigational drug, GSBR-1290, is an orally administered, biased small molecule agonist designed to target the glucagon-like-peptide-1 receptor (GLP-1R). This G-protein-coupled receptor (GPCR) is a recognized and validated therapeutic target for managing both type-2 diabetes mellitus and obesity. Furthermore, Structure Therapeutics is developing other oral small molecule treatments that act on different GPCRs, addressing pulmonary and cardiovascular conditions. For example, ANPA-0073 is a biased agonist aimed at the apelin receptor, a GPCR linked to diseases like idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another compound in their pipeline is LTSE-2578, an oral small molecule that acts as a lysophosphatidic acid 1 receptor antagonist, also being explored for the treatment of IPF. Established in 2016, the company was formerly known as ShouTi Inc. and is headquartered in South San Francisco, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 03:56 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| $0.00 |
| Q4 2024 | Feb 27, 2025 | -$0.22+4.35% vs estimate | $1.78M |
|---|
| Q3 2024 | Nov 13, 2024 | -$0.20-5.26% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
14 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 2 contributors · Median target $90.50.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$1,373.00+$84.70 (+6.57%)
Eli Lilly and Company’s quoted price sits in the upper half of its reported 52-week range, 2.51% below the high.
$45.23+$0.98 (+2.21%)
Septerna Inc’s quoted price sits in the upper half of its reported 52-week range, 11.49% below the high.
$21.24-$0.14 (-0.65%)
Mineralys Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.42% below the high.
$31.93+$0.20 (+0.63%)
Maze Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.48% below the high.
$13.41-$0.01 (-0.07%)
Kailera Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 52.5% below the high.
$5.94$0.00 (0.0%)
BioAge Labs Inc.’s quoted price sits in the lower half of its reported 52-week range, 77.12% below the high.
$26.38+$0.66 (+2.57%)
vTv Therapeutics Inc.’s quoted price sits in the lower half of its reported 52-week range, 40.05% below the high.
$0.62-$0.02 (-3.84%)
Biomea Fusion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 72.2% below the high.
